New drugs for treating Alzheimer’s disease developed by Korean pharmaceutical companies have entered the late phase of clinical trials, and industry watchers are closely monitoring their potential for commercialization.

Aribio has recently submitted an Investigational New Drug (IND) application for its oral treatment candidate AR1001 for Alzheimer’s disease, to eight European countries. Aribio is about to enter the late phase of clinical trials in Europe, following its success in initiating Phase 3 clinical trials in Korea and United States. Additionally, each of the new Alzheimer’s disease drug candidates developed by GemVex, CHA Biotech, and NKMAX has entered Phase 2 clinical trials.

#